Primarily, the present invention relates to compounds of the formula (I) defined below and to their use as herbicides, in particular for controlling broad-leaved weeds and/or weed grasses in crops of useful plants and/or as plant growth regulators for influencing the growth of crops of useful plants. The present invention also relates to herbicidal or plant growth-regulating compositions comprising one or more compounds of the formula (I). Moreover, the present invention relates to processes for preparing the compounds of the formula (I).

The present invention relates to compounds of formula I ##STR00001##
wherein R.sup.1 is methyl; R.sup.1 is methyl, ethyl, CF.sub.3, CH.sub.2OH, cyclopropyl or cyano, or R.sup.1 and R.sup.1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R.sup.2 is hydrogen, methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, cyclopropylmethyl, or hydroxmethyl; R.sup.3 is Cl, F, CF.sub.3, methyl, methoxy, or cyclopropyl; R.sup.4 is hydrogen, methyl, F or Cl; X is N or CH; Y is N or CH; with the proviso that X and Y are not simultaneously CH;
or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer. The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.

The present invention relates to compounds of formula I ##STR00001##
wherein R.sup.1 is methyl; R.sup.1 is methyl, ethyl, CF.sub.3, CH.sub.2OH, cyclopropyl or cyano, or R.sup.1 and R.sup.1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R.sup.2 is hydrogen, methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, cyclopropylmethyl, or hydroxmethyl; R.sup.3 is Cl, F, CF.sub.3, methyl, methoxy, or cyclopropyl; R.sup.4 is hydrogen, methyl, F or Cl; X is N or CH; Y is N or CH; with the proviso that X and Y are not simultaneously CH;
or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer. The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.

A method for preparing an anionic polymerization initiator, a device for manufacturing the same, and an anionic polymerization initiator prepared therefrom is provided. And the method for preparing an anionic polymerization initiator according to the present invention is characterized in that in a continuous reactor an amine compound of Formula 1 and/or Formula 2; an organometallic compound; and/or a conjugated diene compound are introduced in the form of a solution and reacted.

The present invention relates to compounds of formula I

##STR00001##

wherein R.sup.1 is methyl; R.sup.1 is methyl, ethyl, CF.sub.3, CH.sub.2OH, cyclopropyl or cyano, or R.sup.1 and R.sup.1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R.sup.2 is hydrogen, methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, cyclopropylmethyl, or hydroxmethyl; R.sup.3 is Cl, F, CF.sub.3, methyl, methoxy, or cyclopropyl; R.sup.4 is hydrogen, methyl, F or Cl; X is N or CH; Y is N or CH; with the proviso that X and Y are not simultaneously CH;
or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer.

The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.

The present invention relates to compounds of formula I ##STR00001##
wherein R.sup.1 is CH.sub.3 R.sup.1 is methyl, ethyl, CF.sub.3, CH.sub.2OH, cyclopropyl or cyano, or R.sup.1 and R.sup.1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R.sup.2 is hydrogen, methyl, ethyl, isopropyl, tert-butyl or cyclopropyl; R.sup.3 is Cl, F, CF.sub.3, cyano, methyl, methoxy or cyclopropyl; R.sup.4 is hydrogen, methyl or F; X is N or CH; Y is N or CH; with the proviso that X and Y are not simultaneously CH;
or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.

The present invention relates to compounds of formula I ##STR00001##
wherein R.sup.1 is CH.sub.3 R.sup.1 is methyl, ethyl, CF.sub.3, CH.sub.2OH, cyclopropyl or cyano, or R.sup.1 and R.sup.1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R.sup.2 is hydrogen, methyl, ethyl, isopropyl, tert-butyl or cyclopropyl; R.sup.3 is Cl, F, CF.sub.3, cyano, methyl, methoxy or cyclopropyl; R.sup.4 is hydrogen, methyl or F; X is N or CH; Y is N or CH; with the proviso that X and Y are not simultaneously CH;
or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.

The present invention relates to compounds of formula I

##STR00001##

wherein R.sup.1 is CH.sub.3 R.sup.1 is methyl, ethyl, CF.sub.3, CH.sub.2OH, cyclopropyl or cyano, or R.sup.1 and R.sup.1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R.sup.2 is hydrogen, methyl, ethyl, isopropyl, tert-butyl or cyclopropyl; R.sup.3 is Cl, F, CF.sub.3, cyano, methyl, methoxy or cyclopropyl; R.sup.4 is hydrogen, methyl or F; X is N or CH; Y is N or CH; with the proviso that X and Y are not simultaneously CH;
or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof.

The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.

The present invention relates to compounds of formula I

##STR00001##

wherein R.sup.1 is CH.sub.3 R.sup.1 is methyl, ethyl, CF.sub.3, CH.sub.2OH, cyclopropyl or cyano, or R.sup.1 and R.sup.1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R.sup.2 is hydrogen, methyl, ethyl, isopropyl, tert-butyl or cyclopropyl; R.sup.3 is Cl, F, CF.sub.3, cyano, methyl, methoxy or cyclopropyl; R.sup.4 is hydrogen, methyl or F; X is N or CH; Y is N or CH; with the proviso that X and Y are not simultaneously CH;
or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof.

The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.

The present disclosure relates to a method of synthesizing 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine (ceritinib) and/or intermediates thereof, their use as pharmaceuticals and pharmaceutical compositions and the use of intermediates for preparing ceritinib.